Literature DB >> 1654986

Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue.

R Dittadi1, M Gion, V Pagan, A Brazzale, O Del Maschio, A Bargossi, A Busetto, G Bruscagnin.   

Abstract

Epidermal growth factor receptors (EGFr) were measured using a radioligand binding assay, in membrane preparations from 51 human non-small cell lung cancers and in normal tissue of the same patients. The binding characteristics of EGFr were similar in tumour and normal lung membranes (range of dissociation constant of high affinity sites: 0.1-0.6 nM). However, the concentrations in tumours (median, 16.4 fmol mg-1 of protein; range, 1.5-176) were significantly higher than in normal tissues (median, 7.4 fmol mg-1 of protein; range, 1.9-13.4). The receptor levels in normal tissue were normally distributed. It was therefore possible to define a normal/pathologic cut-off level (12.9 fmol mg-1 of protein). In 57% of cases EGFr in cancer was higher than the cut-off. No relationships were found between receptor concentrations and positivity rates of EGFr and histology, stage, lymph node positivity and pT. A trend for a direct relation between receptor positivity and grading was found.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654986      PMCID: PMC1977711          DOI: 10.1038/bjc.1991.390

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

Review 1.  The epidermal growth factor receptor as a multifunctional allosteric protein.

Authors:  J Schlessinger
Journal:  Biochemistry       Date:  1988-05-03       Impact factor: 3.162

2.  Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells.

Authors:  S Gamou; J Hunts; H Harigai; S Hirohashi; Y Shimosato; I Pastan; N Shimizu
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

3.  Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer.

Authors:  D Veale; N Kerr; G J Gibson; A L Harris
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

Review 4.  Epidermal growth factor and its receptor.

Authors:  G N Gill; P J Bertics; J B Santon
Journal:  Mol Cell Endocrinol       Date:  1987-06       Impact factor: 4.102

5.  Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

Authors:  J R Sainsbury; J R Farndon; G K Needham; A J Malcolm; A L Harris
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

6.  Epidermal growth factor receptors in lung tumours.

Authors:  M S Berger; W J Gullick; C Greenfield; S Evans; B J Addis; M D Waterfield
Journal:  J Pathol       Date:  1987-08       Impact factor: 7.996

7.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

8.  Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck.

Authors:  J Ishitoya; M Toriyama; N Oguchi; K Kitamura; M Ohshima; K Asano; T Yamamoto
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

9.  Epidermal growth factor receptors in non-small cell lung cancer.

Authors:  D Veale; T Ashcroft; C Marsh; G J Gibson; A L Harris
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

10.  Expression of epidermal growth factor receptor (EGF-R) in human lung tumours.

Authors:  T Cerny; D M Barnes; P Hasleton; P V Barber; K Healy; W Gullick; N Thatcher
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

View more
  7 in total

1.  Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.

Authors:  J Carlsson; L Shen; J Xiang; J Xu; Q Wei
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967

2.  Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.

Authors:  P Pfeiffer; P P Clausen; K Andersen; C Rose
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

3.  Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma.

Authors:  Jin-Hee Ahn; Sang-We Kim; Seung-Mo Hong; Cheolwon Suh; Woo Kun Kim; In Chul Lee; Jung-Shin Lee
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

4.  Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.

Authors:  Gholamreza Bidkhori; Ali Moeini; Ali Masoudi-Nejad
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

5.  The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival.

Authors:  D Veale; N Kerr; G J Gibson; P J Kelly; A L Harris
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

6.  Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis.

Authors:  P Pfeiffer; E Nexø; S M Bentzen; P P Clausen; K Andersen; C Rose
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

7.  Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas.

Authors:  W J Rachwal; P F Bongiorno; M B Orringer; R I Whyte; S P Ethier; D G Beer
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.